Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. Fundamental Analysis
Laboratorios Farmaceuticos Rovi, S.A. (LABFF) shows moderate financial fundamentals with a PE ratio of 32.39, profit margin of 16.73%, and ROE of 20.65%. The company generates $0.7B in annual revenue with weak year-over-year growth of -7.93%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 57.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze LABFF's fundamental strength across five key dimensions:
Efficiency Score
ExcellentLABFF demonstrates superior asset utilization.
Valuation Score
ModerateLABFF shows balanced valuation metrics.
Growth Score
WeakLABFF faces weak or negative growth trends.
Financial Health Score
ExcellentLABFF maintains a strong and stable balance sheet.
Profitability Score
ExcellentLABFF achieves industry-leading margins.
Key Financial Metrics
Is LABFF Expensive or Cheap?
P/E Ratio
LABFF trades at 32.39 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, LABFF's PEG of -8.73 indicates potential undervaluation.
Price to Book
The market values Laboratorios Farmaceuticos Rovi, S.A. at 6.31 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 22.34 times EBITDA. This signals the market has high growth expectations.
How Well Does LABFF Make Money?
Net Profit Margin
For every $100 in sales, Laboratorios Farmaceuticos Rovi, S.A. keeps $16.73 as profit after all expenses.
Operating Margin
Core operations generate 22.12 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.65 in profit for every $100 of shareholder equity.
ROA
Laboratorios Farmaceuticos Rovi, S.A. generates $13.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Laboratorios Farmaceuticos Rovi, S.A. produces operating cash flow of $174.53M, showing steady but balanced cash generation.
Free Cash Flow
Laboratorios Farmaceuticos Rovi, S.A. generates strong free cash flow of $107.68M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.11 in free cash annually.
FCF Yield
LABFF converts 2.74% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
32.39
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-8.73
vs 25 benchmark
P/B Ratio
Price to book value ratio
6.31
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.02
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.21
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.22
vs 25 benchmark
How LABFF Stacks Against Its Sector Peers
| Metric | LABFF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 32.39 | 29.45 | Neutral |
| ROE | 20.65% | 779.00% | Weak |
| Net Margin | 16.73% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.26 | Strong (Low Leverage) |
| Current Ratio | 3.02 | 4.65 | Strong Liquidity |
| ROA | 13.14% | -19344.00% (disorted) | Strong |
LABFF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Laboratorios Farmaceuticos Rovi, S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
115.59%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
275.14%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
1745.67%
Industry Style: Defensive, Growth, Innovation
High Growth